NCT01238991 - Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Alzheimer's Disease

Interventions

BIOLOGICAL

ACC-001

IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18

BIOLOGICAL

ACC-001

IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18

BIOLOGICAL

ACC-001

IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18

Trial Locations (11)

Meitetsu Hospital, Nagoya

Ibaraki Prefectural Central Hospital, Kasama

Shonan Atsugi Hospital, Atsugi

Kitasato University East Hospital, Sagamihara-shi

Suwa Red Cross Hospital, Suwa

Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka

Osaka Medical College Hospital, Takatsuki

Juntendo University Hospital, Bunkyo-ku

Juntendo Tokyo Koto Geriatric Medical Center, Koto-ku

The Tokyo Jikei University School of Medicine, Minato-ku

Kanto Central Hospital of the Mutual Aid Association of Public School Teachers, Setagaya-ku